DNA Replication-Transcription Collisions Linked to Specific Cancer Mutations

A collaborative study by researchers from the University of Chicago and the University of California, San Francisco has uncovered a connection between certain gene mutations and a specific type of genetic alteration in cancer cells. The research, published in Nature Cancer, reveals how mutations in genes like TP53, CDK12, and SPOP can lead to large tandem duplications (TDs) in DNA, resulting from collisions between transcription and DNA replication processes.

The team analyzed whole genome sequencing data from over 6,000 tumors to identify structural variations in cancer genomes. They discovered that large TDs are particularly common in upper gastrointestinal, prostate, breast, and ovarian cancers. These genetic changes are associated with poor patient survival rates.

Lixing Yang, lead researcher from the University of Chicago, explained the significance of their findings: "When thousands of mutations exist, identifying the specific signature representing an underlying mechanism or contributing factor for a particular subset of mutations is possible using mathematical decomposition."

The study demonstrates that transcription and replication collisions (TRCs) play a crucial role in generating genomic instability in human cancers. These collisions create a unique signature detectable through dosage imbalance at DNA junctions, where extra copies of DNA strands are mistakenly attached to other regions.

Importantly, the research provides new insights into why mutations in certain genes lead to large tandem duplications. "Although this correlation was known, no one had demonstrated that collisions are the underlying reason why CDK12 mutations lead to large tandem duplications," Yang noted.

The findings have potential therapeutic implications, as cancers with high levels of TDs show increased sensitivity to specific drugs, including WEE1, CHK1, and ATR inhibitors. This discovery opens up new avenues for developing targeted treatments for cancers characterized by these genetic alterations, offering hope for improved outcomes in aggressive and difficult-to-treat cases.